Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design

References

• Kühnl A, Grimwade D. Molecular markers in acute myeloid leukaemia. Int J Hematol 2012;96(2):153-63
   PubMed Web of Science ®Google Scholar
• Balgobind B V, Hollink IHIM, Arentsen-Peters STCJM, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011;96(10):1478-87
   PubMedGoogle Scholar
• Marcucci G, Mrózek K, Radmacher MD, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011;117(4):1121-9
   PubMed Web of Science ®Google Scholar
• Greenblatt SM, Nimer SD. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 2014;28(7):1396-406
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89(1):97-108
   PubMed Web of Science ®Google Scholar
• Bacher U, Kern W, Schnittger S, et al. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 2005;90(11):1502-10
   PubMedGoogle Scholar
• Kaspers GJL. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 2012;12(3):405-13
   PubMed Web of Science ®Google Scholar
• Grimwade D. The changing paradigm of prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2012;25(4):419-25
   PubMed Web of Science ®Google Scholar
• Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120(16):3187-205
   PubMed Web of Science ®Google Scholar
• Skalska-Sadowska J, Wachowiak J, Zając-Spychała O, et al. Outcome of refractory and relapsed acute myeloid leukemia in children treated during 2005-2011 - experience of the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG). Contemp Oncol (Poznań, Poland) 2014;18(1):48-53
   PubMedGoogle Scholar
• Kaspers GJL, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013;31(5):599-607
   PubMed Web of Science ®Google Scholar
• Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:43-8
   PubMed Web of Science ®Google Scholar
• Bachas C, Schuurhuis GJ, Reinhardt D, et al. Clinical relevance of molecular aberrations in paediatric Acute Myeloid Leukaemia at first relapse. Br J Haematol 2014;166(6):902-10
   PubMedGoogle Scholar
• Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006;20(7):1217-20
   PubMed Web of Science ®Google Scholar
• Bachas C, Schuurhuis GJ, Hollink IHIM, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 2010;116(15):2752-8
   PubMed Web of Science ®Google Scholar
• Rossi G, Minervini MM, Melillo L, et al. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm’s tumor 1 levels. Ann Hematol 2014;93(7):1149-57
   PubMed Web of Science ®Google Scholar
• Yin JAL, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120(14):2826-35
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Patel K, et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 2014;55(6):1337-44
   PubMed Web of Science ®Google Scholar
• Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood 2012;120(8):1581-8
   PubMed Web of Science ®Google Scholar
• Feller N, van der Velden VHJ, Brooimans RA, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129
   PubMed Web of Science ®Google Scholar
• Goldman JM, Gale RP. What does MRD in leukemia really mean? Leukemia 2014;28(5):1131
   PubMed Web of Science ®Google Scholar
• Terwijn M, Kelder A, Snel AN, et al. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol 2012;34(4):432-41
   PubMedGoogle Scholar
• Van der Velden VHJ, van der Sluijs-Geling A, Gibson BES, et al. Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010;24(9):1599-606
   PubMedGoogle Scholar
• Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006;24(22):3686-92
   PubMedGoogle Scholar
• Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS ONE 2013;8(11):e78897
   PubMed Web of Science ®Google Scholar
• Hokland P, Ommen HB, Nyvold CG, Roug AS. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation. Br J Haematol 2012;158(5):569-80
   PubMedGoogle Scholar
• Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom 2014;86(1):3-14
   PubMed Web of Science ®Google Scholar
• Bachas C, Schuurhuis GJ, Assaraf YG, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012;26(6):1313-20
   PubMed Web of Science ®Google Scholar
• Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010;2(17):17ra9
   PubMed Web of Science ®Google Scholar
• Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012;12(11):767-75
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012;9(10):579-90
   PubMed Web of Science ®Google Scholar
• Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010;28(3):275-80
   PubMed Web of Science ®Google Scholar
• Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000;60(16):4403-11
   PubMed Web of Science ®Google Scholar
• Van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11(18):6520-7
   PubMed Web of Science ®Google Scholar
• Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One 2014; In Press
   PubMedGoogle Scholar
• Van der Pol MA, Feller N, Roseboom M, et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003;88(9):983-93
   PubMedGoogle Scholar
• Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010;115(10):1976-84
   PubMed Web of Science ®Google Scholar
• De Jonge-Peeters SDPWM, Kuipers F, de Vries EGE, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007;62(3):214-26
   PubMed Web of Science ®Google Scholar
• Wulf GG, Wang RY, Kuehnle I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001;98(4):1166-73
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 2001;97(12):3882-9
   PubMedGoogle Scholar
• Moshaver B, van Rhenen A, Kelder A, et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008;26(12):3059-67
   PubMed Web of Science ®Google Scholar
• Smith C, Gasparetto M, Humphries K, et al. Aldehyde dehydrogenases in acute myeloid leukemia. Ann N Y Acad Sci 2014;1310(1):58-68
   PubMedGoogle Scholar
• Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012;119(15):3571-7
   PubMed Web of Science ®Google Scholar
• Miraki-Moud F, Anjos-Afonso F, Hodby KA, et al. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc Natl Acad Sci USA 2013;110(33):13576-81
   PubMed Web of Science ®Google Scholar
• Feller N, van der Velden VHJ, Brooimans RA, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129
   PubMed Web of Science ®Google Scholar
• Van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007;21(8):1700-7
   PubMed Web of Science ®Google Scholar
• Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Rev 2011;25(2):75-81
   PubMed Web of Science ®Google Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17(3):313-19
   PubMed Web of Science ®Google Scholar
• Hoang VT, Hoffmann I, Borowski K, et al. Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia. Methods Mol Biol 2013;1035:217-30
   PubMedGoogle Scholar
• Witte K-E, Ahlers J, Schäfer I, et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol Oncol 2011;28(2):91-9
   PubMed Web of Science ®Google Scholar
• Ran D, Schubert M, Pietsch L, et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009;37(12):1423-34
   PubMedGoogle Scholar
• Schuurhuis GJ, Meel MH, Wouters F, et al. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One 2013;8(11):e78897
   PubMed Web of Science ®Google Scholar
• Cheung AMS, Wan TSK, Leung JCK, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007;21(7):1423-30
   PubMed Web of Science ®Google Scholar
• Roshal M, Chien S, Othus M, et al. The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia. Leukemia 2013;27(3):728-31
   PubMedGoogle Scholar
• HOVON. Available from: www.hovon.nl
   Google Scholar
• Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013;31(31):3889-97
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150(2):264-78
   PubMed Web of Science ®Google Scholar
• Woll PS, Kjällquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014;25(6):794-808
   PubMed Web of Science ®Google Scholar
• Radojkovic M, Tosic N, Colovic N, et al. Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia. Ann Clin Lab Sci 2012;42(2):186-90
   PubMedGoogle Scholar
• Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481(7382):506-10
   PubMed Web of Science ®Google Scholar
• Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene 2013;32(2):135-40
   PubMed Web of Science ®Google Scholar
• Tie R, Zhang T, Fu H, et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2014;9(6):e93353
   PubMed Web of Science ®Google Scholar
• Ho PA, Kutny MA, Alonzo TA, et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2011;57(2):204-9
   PubMedGoogle Scholar
• De Leeuw DC, Denkers F, Olthof MC, et al. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res 2014;74(7):2094-105
   PubMedGoogle Scholar
• Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014;25(3):379-92
   PubMed Web of Science ®Google Scholar
• Groen RWJ, Noort WA, Raymakers RA, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012;120(3):e9-e16
   PubMed Web of Science ®Google Scholar
• Williams SA, Anderson WC, Santaguida MT, Dylla SJ. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest 2013;93(9):970-82
   PubMed Web of Science ®Google Scholar
• Schuringa JJ, Schepers H. Ex vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells. Methods Mol Biol 2009;538:287-300
   PubMedGoogle Scholar
• Mardiros A, Brown CE, Budde LE, et al. Acute myeloid leukemia therapeutics: CARs in the driver’s seat. Oncoimmunology 2013;2(12):e27214
   Google Scholar
• Goldmacher VS, Kovtun Y V. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2011;2(3):397-416
   PubMedGoogle Scholar
• Van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11(18):6520-7
   PubMed Web of Science ®Google Scholar
• Wang L, Gao L, Xu S, et al. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome. J Hematol Oncol 2013;6(1):85
   PubMedGoogle Scholar
• Plesa A, Elhamri M, Clapisson G, et al. Higher percentage of CD34(+)CD38(-) cells detected by multi-parameter flow cytometry from leukapheresis products predict unsustained complete remission in AML. Leuk Lymphoma 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Gentles AJ, Plevritis SK, Page P, et al. Association of a Leukemic Stem Cell Gene in Acute Myeloid Leukemia. JAMA 2010;304(24):2706-15
   PubMed Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J, et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011;96(12):1792-8
   PubMed Web of Science ®Google Scholar
• Gerber JM, Smith BD, Ngwang B, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012;119(15):3571-7
   PubMed Web of Science ®Google Scholar
• Bartholdy B, Christopeit M, Will B, et al. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest 2014;124(3):1158-67
   PubMed Web of Science ®Google Scholar
• De Leeuw DC, Denkers F, Olthof MC, et al. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res 2014;74(7):2094-105
   PubMedGoogle Scholar
• Metzeler KH, Maharry K, Kohlschmidt J, et al. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 2013;27(10):2023-31
   PubMedGoogle Scholar
• Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010;16(8):903-8
   PubMed Web of Science ®Google Scholar
• Thol F, Winschel C, Sonntag A-K, et al. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Ann Hematol 2013;92(3):315-23
   PubMed Web of Science ®Google Scholar
• Diffner E, Beck D, Gudgin E, et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood 2013;121(12):2289-300
   PubMed Web of Science ®Google Scholar
• Heidel FH, Bullinger L, Arreba-Tutusaus P, et al. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med 2013;210(1):15-22
   PubMed Web of Science ®Google Scholar
• Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012;120(6):1290-8
   PubMed Web of Science ®Google Scholar
• Wang L, Gao L, Xu S, et al. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). Ann Hematol 2014;93(10):1685-94
   PubMed Web of Science ®Google Scholar
• Hwang K, Park C-J, Jang S, et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol 2012;91(10):1541-6
   PubMedGoogle Scholar
• Walter RB, Laszlo GS, Lionberger JM, et al. Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia 2014; doi; 10.1038/leu.2014.107. [Epub ahead of print]
   Google Scholar
• Schwemmlein M, Peipp M, Barbin K, et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol 2006;133(2):141-51
   PubMedGoogle Scholar
• Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009;5(1):31-42
   PubMed Web of Science ®Google Scholar
• Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12(10):1167-74
   PubMed Web of Science ®Google Scholar
• Noordhuis P, Terwijn M, Rutten A, et al. Targeting of CLEC12A in acute myeloid leukemia by antibody-drug-conjugates and bispecific CLL-1xCD3 BiTE antibody. Blood 2010. 116([ ASH Annual Meeting Abstracts 2890
   Google Scholar
• Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138(2):286-99
   PubMed Web of Science ®Google Scholar
• Theocharides APA, Jin L, Cheng P-Y, et al. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 2012;209(10):1883-99
   PubMed Web of Science ®Google Scholar
• Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013;27(5):1107-15
   PubMed Web of Science ®Google Scholar
• Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013;27(4):964-7
   PubMed Web of Science ®Google Scholar
• Al Hussaini M, Ritchey J, Rettig M, et al. Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs®). Blood 2013. 122(21), ASH Annual Meeting Abstracts
   Google Scholar
• Zhao X, Singh S, Pardoux C, et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 2010;95(1):71-8
   PubMed Web of Science ®Google Scholar
• Askmyr M, Ågerstam H, Hansen N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013;121(18):3709-13
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol 2013;98(6):627-33
   PubMed Web of Science ®Google Scholar
• Saito Y, Yuki H, Kuratani M, et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med 2013;5(181):181ra52
   PubMedGoogle Scholar
• Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA 2013;110(50):20224-9
   PubMed Web of Science ®Google Scholar
• Zhang H, Mi JQ, Fang H, et al. Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci USA 2013;110(14):5606-11
   PubMedGoogle Scholar
• Weidenaar AC, Ter Elst A, Kampen KR, et al. Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584. Mol Cancer Res 2013;11(4):339-48
   PubMedGoogle Scholar
• Herrmann H, Blatt K, Shi J, et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 2012;3(12):1588-99
   PubMed Web of Science ®Google Scholar
• Beurlet S, Omidvar N, Gorombei P, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood 2013;122(16):2864-76
   PubMedGoogle Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013;12(3):329-41
   PubMed Web of Science ®Google Scholar
• Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood 2013;122(11):1900-13
   PubMed Web of Science ®Google Scholar
• Roberts KG, Smith AM, McDougall F, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 2010;70(13):5438-47
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Malek SN, et al. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011;8(4):399-411
   PubMed Web of Science ®Google Scholar
• Su YC, Li SC, Wu YC, et al. Resveratrol downregulates interleukin-6-stimulated sonic hedgehog signaling in human acute myeloid leukemia. Evid Based Complement Alternat Med 2013;2013:547430
   PubMed Web of Science ®Google Scholar
• Wu EJ, Goussetis DJ, Beauchamp E, et al. Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. Cancer Biol Ther 2014;15(4):473-8
   PubMed Web of Science ®Google Scholar